TRENTON, NJ – Attorney General Gurbir S. Grewal joined 42 other states Monday in releasing the full, unredacted complaint against some of the nation’s largest generic drug manufacturers after a U.S. District Court Judge granted the states’ motion to unseal the complaint.
The complaint accuses 20 drug companies and 16 individual defendants – drug company executives responsible for sales, marketing, pricing and operations — of conspiring to artificially inflate the prices of more than 100 generic drugs in violation of federal and state antitrust and consumer protection laws.
More than half of the corporate defendants are based in New Jersey, and five of the individual defendants reside in the state.
Here is the list of defendants named in today’s lawsuit:
- Teva Pharmaceuticals USA, Inc., North Wales, PA
- Sandoz, Inc., Princeton, NJ
- Mylan Pharmaceuticals Inc., Canonsburg, PA
- Actavis Holdco US, Inc., Parsippany, NJ
- Actavis Pharma, Inc., Parsippany, NJ
- Amneal Pharmaceuticals, Inc., Bridgewater, NJ
- Apotex Corp., Weston, FL
- Aurobindo Pharma U.S.A., Inc., Dayton, NJ
- Breckenridge Pharmaceutical, Inc., Fairfield, NJ
- Dr. Reddy’s Laboratories, Inc., Princeton, NJ
- Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ
- Greenstone LLC, North Peapack, NJ
- Lannett Company, Inc., Philadelphia, PA
- Lupin Pharmaceuticals, Inc., Baltimore, MD
- Par Pharmaceutical Companies, Inc., Chestnut Ridge, NY
- Pfizer, Inc., New York, NY
- Taro Pharmaceuticals USA, Inc., Hawthorne, NY
- Upsher-Smith Laboratories, LLC, Maple Grove, MN
- Wockhardt USA, LLC, Parsippany, NJ
- Zydus Pharmaceuticals (USA), Inc., North Pennington, NJ
Contained in the unredacted complaint unsealed today are emails between generic drug manufacturers coordinating their response to a Congressional inquiry, emails enforcing “fair share” and “playing nice in the sandbox” market allocation, “fluff pricing” strategy and other coordination to artificially inflate prices, hinder competition and unreasonably restrain trade across the industry.
“The information made public today paints a picture of some of our nation’s largest generic pharmaceutical companies conspiring to fix prices and allocate market shares for drugs that many people rely on to survive,” said Attorney General Grewal. “The defendants actively avoided written communications about their illegal conspiracy, but that did not stop our investigation from uncovering messages that open a window into their illegal actions to drive up drug prices for consumers in New Jersey and across the country.”
To view the full unredacted complaint, click here.